)

Inventiva (IVA) investor relations material
Inventiva Investor & Analyst Day summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Strategic direction and future plans
Transitioning from a development-stage to a commercial-stage company, leveraging new management and leadership to prepare for the 2028 launch of lanifibranor, an oral therapy for MASH.
Emphasizing a holistic approach to MASH, integrating liver-directed and cardiometabolic therapies, and anticipating a future with more combination treatments and broader physician involvement.
Preparing for a market where most patients may already be on GLP-1 agonists, with lanifibranor positioned as an add-on or alternative for those needing additional liver-directed efficacy.
Anticipating increased disease awareness, earlier diagnosis, and a shift toward prevention and integrated metabolic health services by 2028.
Organization reinforced with experienced executives and new CEO to support leadership in MASH and commercial launch.
Financial guidance and market outlook
Raised over $411 million in PIPE financing, ensuring strong financial positioning to support clinical development and commercialization.
The addressable U.S. market for MASH is rapidly expanding, with diagnosed and under-treatment patients up 70% in four years, now at 367,000, and expected to grow further as awareness and screening improve.
MASH affects approximately 1.9 million diagnosed patients in the US, with significant unmet need for effective, liver-directed therapies.
Real-world practice is shifting toward non-invasive diagnostics and broader use of GLP-1s, with payers and guidelines expected to adapt as new therapies like lanifibranor become available.
The company is preparing for reimbursement and adoption challenges, emphasizing the simplicity, tolerability, and broad metabolic benefits of lanifibranor.
Lanifibranor: Mechanism, efficacy, and differentiation
Lanifibranor is a once-daily, oral, pan-PPAR agonist designed to address intrahepatic fibrosis and extrahepatic metabolic dysfunction.
Demonstrated both MASH resolution and direct fibrosis regression at 24 weeks in Phase 2b, with additional cardiometabolic benefits.
Intellectual property protection extends through 2041, supporting durable market exclusivity.
Differentiation centers on dual intrahepatic and extrahepatic benefits, oral administration, and potential to address high-risk MASH patients.
Favorable safety profile with manageable side effects; most common AEs include diarrhea, nausea, and peripheral edema.
Next Inventiva earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage